From Microscale Devices to 3D Printing: Advances in Fabrication of 3D Cardiovascular Tissues.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28057791.
- Also identified by DOI 10.1161/CIRCRESAHA.116.308538 and PMC identifier 5224928.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current strategies for engineering cardiovascular cells and tissues have yielded a variety of sophisticated tools for studying disease mechanisms, for development of drug therapies, and for fabrication of tissue equivalents that may have application in future clinical use. These efforts are motivated by the need to extend traditional 2-dimensional (2D) cell culture systems into 3D to more accurately replicate in vivo cell and tissue function of cardiovascular structures. Developments in microscale devices and bioprinted 3D tissues are beginning to supplant traditional 2D cell cultures and preclinical animal studies that have historically been the standard for drug and tissue development. These new approaches lend themselves to patient-specific diagnostics, therapeutics, and tissue regeneration. The emergence of these technologies also carries technical challenges to be met before traditional cell culture and animal testing become obsolete. Successful development and validation of 3D human tissue constructs will provide powerful new paradigms for more cost effective and timely translation of cardiovascular tissue equivalents.
Medical subject headings
- Myocytes, Cardiac
- Printing, Three-Dimensional
- Tissue Engineering
- Tissue Scaffolds